Gastrointestinal Stromal Tumor (GIST) – Pipeline Review, H2 2017

Global Markets Direct’s, ‘Gastrointestinal Stromal Tumor (GIST) – Pipeline Review, H2 2017’, provides an overview of the Gastrointestinal Stromal Tumor (GIST) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Gastrointestinal Stromal Tumor (GIST), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Gastrointestinal Stromal Tumor (GIST) and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Gastrointestinal Stromal Tumor (GIST)

The report reviews pipeline therapeutics for Gastrointestinal Stromal Tumor (GIST) by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Gastrointestinal Stromal Tumor (GIST) therapeutics and enlists all their major and minor projects

The report assesses Gastrointestinal Stromal Tumor (GIST) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Gastrointestinal Stromal Tumor (GIST)

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Gastrointestinal Stromal Tumor (GIST)

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Gastrointestinal Stromal Tumor (GIST) pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

AB Science SA

Advanced Accelerator Applications SA

Ariad Pharmaceuticals Inc

Arog Pharmaceuticals Inc

ArQule Inc

Array BioPharma Inc

Ascentage Pharma Group Corp Ltd

Astex Pharmaceuticals Inc

Blueprint Medicines Corp

Boston Biomedical Inc

Calithera Biosciences Inc

Celldex Therapeutics Inc

Chipscreen Biosciences Ltd

Deciphera Pharmaceuticals LLC

Eli Lilly and Co

Exelixis Inc

F. Hoffmann-La Roche Ltd

Hanmi Pharmaceuticals Co Ltd

Horizon Pharma Plc

Immunicum AB

Jiangsu Hengrui Medicine Co Ltd

Loxo Oncology Inc

Merck & Co Inc

Natco Pharma Ltd

Nerviano Medical Sciences Srl

Novartis AG

Omeros Corp

Pharma Mar SA

Plexxikon Inc

Rhizen Pharmaceuticals SA

Taiho Pharmaceutical Co Ltd

Xencor Inc

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 7

List of Figures 8

Introduction 9

Global Markets Direct Report Coverage 9

Gastrointestinal Stromal Tumor (GIST) - Overview 10

Gastrointestinal Stromal Tumor (GIST) - Therapeutics Development 11

Pipeline Overview 11

Pipeline by Companies 12

Pipeline by Universities/Institutes 15

Products under Development by Companies 16

Products under Development by Universities/Institutes 19

Gastrointestinal Stromal Tumor (GIST) - Therapeutics Assessment 20

Assessment by Target 20

Assessment by Mechanism of Action 23

Assessment by Route of Administration 27

Assessment by Molecule Type 29

Gastrointestinal Stromal Tumor (GIST) - Companies Involved in Therapeutics Development 31

AB Science SA 31

Advanced Accelerator Applications SA 31

Ariad Pharmaceuticals Inc 32

Arog Pharmaceuticals Inc 32

ArQule Inc 32

Array BioPharma Inc 33

Ascentage Pharma Group Corp Ltd 33

Astex Pharmaceuticals Inc 34

Blueprint Medicines Corp 34

Boston Biomedical Inc 34

Calithera Biosciences Inc 35

Celldex Therapeutics Inc 35

Chipscreen Biosciences Ltd 36

Deciphera Pharmaceuticals LLC 36

Eli Lilly and Co 37

Exelixis Inc 37

F. Hoffmann-La Roche Ltd 38

Hanmi Pharmaceuticals Co Ltd 38

Horizon Pharma Plc 38

Immunicum AB 39

Jiangsu Hengrui Medicine Co Ltd 39

Loxo Oncology Inc 40

Merck & Co Inc 40

Natco Pharma Ltd 41

Nerviano Medical Sciences Srl 41

Novartis AG 42

Omeros Corp 42

Pharma Mar SA 43

Plexxikon Inc 43

Rhizen Pharmaceuticals SA 44

Taiho Pharmaceutical Co Ltd 44

Xencor Inc 45

Gastrointestinal Stromal Tumor (GIST) - Drug Profiles 46

aldoxorubicin hydrochloride - Drug Profile 46

Product Description 46

Mechanism Of Action 46

R&D Progress 46

amcasertib - Drug Profile 64

Product Description 64

Mechanism Of Action 64

R&D Progress 64

anagrelide hydrochloride CR - Drug Profile 67

Product Description 67

Mechanism Of Action 67

R&D Progress 67

APG-1351 - Drug Profile 68

Product Description 68

Mechanism Of Action 68

R&D Progress 68

binimetinib - Drug Profile 69

Product Description 69

Mechanism Of Action 69

R&D Progress 69

BLU-285 - Drug Profile 78

Product Description 78

Mechanism Of Action 78

R&D Progress 78

buparlisib hydrochloride - Drug Profile 84

Product Description 84

Mechanism Of Action 84

R&D Progress 84

cabozantinib s-malate - Drug Profile 90

Product Description 90

Mechanism Of Action 90

R&D Progress 90

CB-839 - Drug Profile 112

Product Description 112

Mechanism Of Action 112

R&D Progress 112

CDX-0158 - Drug Profile 122

Product Description 122

Mechanism Of Action 122

R&D Progress 122

CHMFLKIT-110 - Drug Profile 125

Product Description 125

Mechanism Of Action 125

R&D Progress 125

crenigacestat - Drug Profile 126

Product Description 126

Mechanism Of Action 126

R&D Progress 126

crenolanib besylate - Drug Profile 128

Product Description 128

Mechanism Of Action 128

R&D Progress 128

CS-2164 - Drug Profile 132

Product Description 132

Mechanism Of Action 132

R&D Progress 132

dabrafenib mesylate + trametinib dimethyl sulfoxide - Drug Profile 133

Product Description 133

Mechanism Of Action 133

R&D Progress 133

DCC-2618 - Drug Profile 141

Product Description 141

Mechanism Of Action 141

R&D Progress 141

everolimus - Drug Profile 145

Product Description 145

Mechanism Of Action 145

R&D Progress 145

HM-95573 - Drug Profile 157

Product Description 157

Mechanism Of Action 157

R&D Progress 157

ilixadencel - Drug Profile 159

Product Description 159

Mechanism Of Action 159

R&D Progress 159

interferon gamma-1b - Drug Profile 168

Product Description 168

Mechanism Of Action 168

R&D Progress 168

larotrectinib - Drug Profile 173

Product Description 173

Mechanism Of Action 173

R&D Progress 173

masitinib - Drug Profile 180

Product Description 180

Mechanism Of Action 180

R&D Progress 180

miransertib - Drug Profile 197

Product Description 197

Mechanism Of Action 197

R&D Progress 197

NMSP-088 - Drug Profile 201

Product Description 201

Mechanism Of Action 201

R&D Progress 201

NRCAN-019 - Drug Profile 202

Product Description 202

Mechanism Of Action 202

R&D Progress 202

onalespib - Drug Profile 204

Product Description 204

Mechanism Of Action 204

R&D Progress 204

pembrolizumab - Drug Profile 208

R&D Progress 209

Peptide to Antagonize GRPR for Oncology - Drug Profile 274

Product Description 274

Mechanism Of Action 274

R&D Progress 274

pexidartinib hydrochloride - Drug Profile 275

Product Description 275

Mechanism Of Action 275

R&D Progress 275

PLX-9486 - Drug Profile 280

Product Description 280

Mechanism Of Action 280

R&D Progress 280

PM-184 - Drug Profile 281

Product Description 281

Mechanism Of Action 281

R&D Progress 281

ponatinib hydrochloride - Drug Profile 283

Product Description 283

Mechanism Of Action 283

R&D Progress 283

SF-1126 - Drug Profile 299

Product Description 299

Mechanism Of Action 299

R&D Progress 299

SHR-1020 - Drug Profile 302

Product Description 302

Mechanism Of Action 302

R&D Progress 302

Small Molecule to Antagonize GPR20 for Acute Myeloid Leukemia and Gastro-Intestinal Stromal Tumors - Drug Profile 304

Product Description 304

Mechanism Of Action 304

R&D Progress 304

Small Molecules to Inhibit c-Kit for Gastrointestinal Stromal Tumor - Drug Profile 305

Product Description 305

Mechanism Of Action 305

R&D Progress 305

TAS-116 - Drug Profile 306

Product Description 306

Mechanism Of Action 306

R&D Progress 306

umbralisib tosylate - Drug Profile 307

Product Description 307

Mechanism Of Action 307

R&D Progress 307

vemurafenib - Drug Profile 318

Product Description 318

Mechanism Of Action 318

R&D Progress 318

WBZ-4 - Drug Profile 326

Product Description 326

Mechanism Of Action 326

R&D Progress 326

XmAb-18087 - Drug Profile 327

Product Description 327

Mechanism Of Action 327

R&D Progress 327

Gastrointestinal Stromal Tumor (GIST) - Dormant Projects 328

Gastrointestinal Stromal Tumor (GIST) - Discontinued Products 329

Gastrointestinal Stromal Tumor (GIST) - Product Development Milestones 330

Featured News & Press Releases 330

Nov 10, 2017: Blueprint Medicines Announces New Data from Ongoing Phase 1 Clinical Trial of BLU-285 in Patients with Advanced Gastrointestinal Stromal Tumors Showing Strengthened Clinical Activity across Spectrum of KIT and PDGFR alpha Genotypes 330

Nov 10, 2017: Deciphera Pharmaceuticals Reports Data Analysis from the Ongoing Phase 1 Clinical Trial of DCC-2618 at the Annual Meeting of The Connective Tissue Oncology Society 332

Nov 01, 2017: Blueprint Medicines Announces Publication of BLU-285 Translational Data 333

Sep 11, 2017: Deciphera Pharmaceuticals Reports Updated Data from Ongoing Phase 1 Clinical Study of DCC-2618 at the European Society of Medical Oncology 2017 Congress 334

Aug 31, 2017: Deciphera Pharmaceuticals to Present Updated Data from Ongoing Phase 1 Study of DCC-2618 at the 2017 European Society for Medical Clinical Oncology Annual Congress 335

Aug 02, 2017: Blueprint Medicines Provides Update on Clinical Program of its Cancer Drug, BLU-285 336

Jun 05, 2017: Blueprint Medicines Announces New Phase 1 Clinical Data for BLU-285 in Advanced Gastrointestinal Stromal Tumors and Plans to Pursue Expedited Development in Patients with a PDGFRa D842V Mutation 337

Jun 05, 2017: Deciphera Pharmaceuticals Reports Updated Phase 1 Clinical Study Results with DCC-2618 at 2017 American Society of Clinical Oncology Annual Meeting 339

May 18, 2017: Deciphera Pharmaceuticals to Report Phase 1 Clinical Study Results with DCC-2618 at the 2017 American Society of Clinical Oncology Annual Meeting 340

May 17, 2017: Blueprint Medicines to Present New Data from Ongoing Phase 1 Clinical Trial of BLU-285 in Patients with Advanced Gastrointestinal Stromal Tumors at 2017 ASCO Annual Meeting 340

Apr 03, 2017: Translational Research Results Confirm The Broad Activity of DCC-2618 in GIST Patients With Difficult to Treat Drug Resistant KIT Mutations 341

Nov 30, 2016: Blueprint Medicines Announces Proof-of-Concept Data from Phase 1 Clinical Trial of BLU-285 in Patients with Advanced Gastrointestinal Stromal Tumors 341

Nov 30, 2016: Results from 3 ground-breaking studies show early benefit to patients 343

Nov 16, 2016: Arog Pharmaceuticals Receives FDA Fast Track Designation for Crenolanib for Advanced Gastrointestinal Stromal Tumors with a D842V Mutation in the PDGFRA Gene 346

Nov 15, 2016: Blueprint Medicines to Present Preliminary Data from Ongoing Phase 1 Clinical Trial for BLU-285 at 28th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics 346

Appendix 348

Methodology 348

Coverage 348

Secondary Research 348

Primary Research 348

Expert Panel Validation 348

Contact Us 348

Disclaimer 349

List of Tables

List of Tables

Number of Products under Development for Gastrointestinal Stromal Tumor (GIST), H2 2017 11

Number of Products under Development by Companies, H2 2017 13

Number of Products under Development by Companies, H2 2017 (Contd..1), H2 2017 14

Number of Products under Development by Universities/Institutes, H2 2017 15

Products under Development by Companies, H2 2017 16

Products under Development by Companies, H2 2017 (Contd..1), H2 2017 17

Products under Development by Companies, H2 2017 (Contd..2), H2 2017 18

Products under Development by Universities/Institutes, H2 2017 19

Number of Products by Stage and Target, H2 2017 21

Number of Products by Stage and Target, H2 2017 (Contd..1), H2 2017 22

Number of Products by Stage and Mechanism of Action, H2 2017 24

Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..1), H2 2017 25

Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..2), H2 2017 26

Number of Products by Stage and Route of Administration, H2 2017 28

Number of Products by Stage and Molecule Type, H2 2017 30

Gastrointestinal Stromal Tumor (GIST) – Pipeline by AB Science SA, H2 2017 31

Gastrointestinal Stromal Tumor (GIST) – Pipeline by Advanced Accelerator Applications SA, H2 2017 31

Gastrointestinal Stromal Tumor (GIST) – Pipeline by Ariad Pharmaceuticals Inc, H2 2017 32

Gastrointestinal Stromal Tumor (GIST) – Pipeline by Arog Pharmaceuticals Inc, H2 2017 32

Gastrointestinal Stromal Tumor (GIST) – Pipeline by ArQule Inc, H2 2017 33

Gastrointestinal Stromal Tumor (GIST) – Pipeline by Array BioPharma Inc, H2 2017 33

Gastrointestinal Stromal Tumor (GIST) – Pipeline by Ascentage Pharma Group Corp Ltd, H2 2017 33

Gastrointestinal Stromal Tumor (GIST) – Pipeline by Astex Pharmaceuticals Inc, H2 2017 34

Gastrointestinal Stromal Tumor (GIST) – Pipeline by Blueprint Medicines Corp, H2 2017 34

Gastrointestinal Stromal Tumor (GIST) – Pipeline by Boston Biomedical Inc, H2 2017 35

Gastrointestinal Stromal Tumor (GIST) – Pipeline by Calithera Biosciences Inc, H2 2017 35

Gastrointestinal Stromal Tumor (GIST) – Pipeline by Celldex Therapeutics Inc, H2 2017 36

Gastrointestinal Stromal Tumor (GIST) – Pipeline by Chipscreen Biosciences Ltd, H2 2017 36

Gastrointestinal Stromal Tumor (GIST) – Pipeline by Deciphera Pharmaceuticals LLC, H2 2017 36

Gastrointestinal Stromal Tumor (GIST) – Pipeline by Eli Lilly and Co, H2 2017 37

Gastrointestinal Stromal Tumor (GIST) – Pipeline by Exelixis Inc, H2 2017 37

Gastrointestinal Stromal Tumor (GIST) – Pipeline by F. Hoffmann-La Roche Ltd, H2 2017 38

Gastrointestinal Stromal Tumor (GIST) – Pipeline by Hanmi Pharmaceuticals Co Ltd, H2 2017 38

Gastrointestinal Stromal Tumor (GIST) – Pipeline by Horizon Pharma Plc, H2 2017 39

Gastrointestinal Stromal Tumor (GIST) – Pipeline by Immunicum AB, H2 2017 39

Gastrointestinal Stromal Tumor (GIST) – Pipeline by Jiangsu Hengrui Medicine Co Ltd, H2 2017 40

Gastrointestinal Stromal Tumor (GIST) – Pipeline by Loxo Oncology Inc, H2 2017 40

Gastrointestinal Stromal Tumor (GIST) – Pipeline by Merck & Co Inc, H2 2017 41

Gastrointestinal Stromal Tumor (GIST) – Pipeline by Natco Pharma Ltd, H2 2017 41

Gastrointestinal Stromal Tumor (GIST) – Pipeline by Nerviano Medical Sciences Srl, H2 2017 42

Gastrointestinal Stromal Tumor (GIST) – Pipeline by Novartis AG, H2 2017 42

Gastrointestinal Stromal Tumor (GIST) – Pipeline by Omeros Corp, H2 2017 43

Gastrointestinal Stromal Tumor (GIST) – Pipeline by Pharma Mar SA, H2 2017 43

Gastrointestinal Stromal Tumor (GIST) – Pipeline by Plexxikon Inc, H2 2017 44

Gastrointestinal Stromal Tumor (GIST) – Pipeline by Rhizen Pharmaceuticals SA, H2 2017 44

Gastrointestinal Stromal Tumor (GIST) – Pipeline by Taiho Pharmaceutical Co Ltd, H2 2017 44

Gastrointestinal Stromal Tumor (GIST) – Pipeline by Xencor Inc, H2 2017 45

Gastrointestinal Stromal Tumor (GIST) – Dormant Projects, H2 2017 328

Gastrointestinal Stromal Tumor (GIST) – Discontinued Products, H2 2017 329

List of Figures

List of Figures

Number of Products under Development for Gastrointestinal Stromal Tumor (GIST), H2 2017 11

Number of Products under Development by Companies, H2 2017 12

Number of Products under Development by Universities/Institutes, H2 2017 15

Number of Products by Top 10 Targets, H2 2017 20

Number of Products by Stage and Top 10 Targets, H2 2017 20

Number of Products by Top 10 Mechanism of Actions, H2 2017 23

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017 23

Number of Products by Routes of Administration, H2 2017 27

Number of Products by Stage and Routes of Administration, H2 2017 27

Number of Products by Molecule Types, H2 2017 29

Number of Products by Stage and Molecule Types, H2 2017 29

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports